 |
59 Diseases |  |
17 Trials |
|
17 Trials |  |
538 News |  |
| «12345678» |
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Phase classification: Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy (clinicaltrials.gov) - Jan 8, 2021
P2, N=35, Recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2
- || Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial initiation date, Trial primary completion date: Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 (clinicaltrials.gov) - Jan 7, 2021
P2, N=80, Not yet recruiting, Sponsor: AgelessRx
Not yet recruiting --> Recruiting | Phase classification: PN/A --> P2 Trial completion date: May 2021 --> Oct 2021 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Apr 2021 --> Aug 2021
- || Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial initiation date, Trial primary completion date: Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome (clinicaltrials.gov) - Jan 7, 2021
P2, N=60, Not yet recruiting, Sponsor: AgelessRx
Trial completion date: May 2021 --> Oct 2021 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: Apr 2021 --> Aug 2021 Trial completion date: Jun 2021 --> Oct 2021 | Initiation date: Nov 2020 --> Feb 2021 | Trial primary completion date: May 2021 --> Aug 2021
- Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
[VIRTUAL] Low Dose Naltrexone () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2829;
Patients using LDN, compared to previous therapies, reported improved QOL and pain control. Despite improved pain control, patient activity level does not appear to increase with the use of LDN, which was unexpected.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial, New trial: Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy (clinicaltrials.gov) - Dec 22, 2020
P=N/A, N=35, Not yet recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- | New trial: Psychobiological Mechanisms Underlying Chronic Pain (clinicaltrials.gov) - Dec 19, 2020
P=N/A, N=100, Not yet recruiting, Sponsor: susanne becker
- || Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Clinical, Review, Journal: Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review. (Pubmed Central) - Dec 16, 2020
Low-dose naltrexone may represent a cost-effective and successful treatment modality in nongeneralized Hailey-Hailey disease without serious adverse effects. Future prospective studies are needed to investigate this interesting therapeutic option.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Low-dose naltrexone in Hailey-Hailey disease: the importance of dosing. (Pubmed Central) - Dec 2, 2020
One interesting observation we made in the article was the response of one patient to the standard higher dose (50 mg) of naltrexone. Two previous studies that used the 50 mg dose in HHD patients (3 patients total) had failed to show any positive response.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: The lowdown on low-dose naltrexone. (Pubmed Central) - Nov 19, 2020
Patients may ask you about LDN as a treatment option for a variety of inflammatory skin conditions, specifically in comparison to more traditional systemic treatments. It is important for dermatologists to know what LDN is, how it works, how to prescribe it, and what side effects should be monitored.
- | Remitch (nalfurafine) / Toray, Mitsubishi Tanabe, Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice. (Pubmed Central) - Nov 2, 2020
NMF prevented the ADE in both sexes, while selective KOP-r antagonist nor-BNI had no effect. Our new study suggests that a combination of clinically-utilized, potent KOP-r agonist NFF with low-dose NTX has therapeutic potential in alcohol "relapse" treatment.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation-wide register-based controlled before-after study. (Pubmed Central) - Oct 30, 2020
The findings show an association between the initiation of persistent LDN use and reduced consumption of several psychotropic medicines and antiepileptics. Beneficial effects of LDN in the treatment of psychiatric diseases cannot be ruled out.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Preclinical, Journal: In vitro evaluation of Naltrexone HCl 1% Topical Cream in XemaTop™ for psoriasis. (Pubmed Central) - Oct 30, 2020
Low-dose Naltrexone in XemaTop™ was stable within 180 days when stored under refrigerated or ambient conditions. These results provide a basis for a clinical evaluation of 1% Naltrexone HCl in XemaTop™ in psoriasis patients.
- |||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19 (clinicaltrials.gov) - Oct 27, 2020
P2, N=80, Not yet recruiting, Sponsor: AgelessRx
- |||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome (clinicaltrials.gov) - Oct 27, 2020
P2, N=60, Not yet recruiting, Sponsor: AgelessRx
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Low-Dose Naltrexone: An Inexpensive Medicine for Many Ills? https://t.co/lAApQm8Bvx via @medscape (Twitter) - Oct 23, 2020
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed: EMCS-NDPH: Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children (clinicaltrials.gov) - Oct 23, 2020
P1/2, N=150, Active, not recruiting, Sponsor: Boston Children's Hospital
These results provide a basis for a clinical evaluation of 1% Naltrexone HCl in XemaTop™ in psoriasis patients. Recruiting --> Active, not recruiting
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open: Low-dose Naltrexone for Bladder Pain Syndrome (clinicaltrials.gov) - Oct 22, 2020
P2, N=40, Recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Preclinical, Journal, Adverse events: Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study. (Pubmed Central) - Oct 20, 2020
In conclusion, intranasal low-dose naltrexone counteracted morphine and oxycodone induced gastrointestinal and CNS side effects without impairing opioid analgesia. It is a candidate to be a valid clinical strategy deserving deep analysis.
- Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
[VIRTUAL] L122. Can We Use Opioid Antagonist for Pain Management? How Does It Work? () - Oct 17, 2020 - Abstract #ASA2020ASA_2031;
Session Learning Objective 2 Demonstrate the efficacy of low dose naltrexone (LDN) as modality for pain management. Session Learning Objective 3 Summarize the clinical indication for LDN.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Oct 13, 2020
P=N/A, N=30, Suspended, Sponsor: University of Alabama at Birmingham
Session Learning Objective 3 Summarize the clinical indication for LDN. Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Low dose naltrexone (Twitter) - Oct 9, 2020
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date: IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone (clinicaltrials.gov) - Sep 7, 2020
P4, N=44, Not yet recruiting, Sponsor: NorthShore University HealthSystem
Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021 Initiation date: Apr 2020 --> Sep 2020
- | Remitch (nalfurafine) / Toray, Mitsubishi Tanabe, Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Combination of clinically utilized kappa opioid receptor agonist nalfurafine with low-dose naltrexone reduces excessive alcohol drinking in male and female mice. (Pubmed Central) - Sep 5, 2020
Initiation date: Apr 2020 --> Sep 2020 The clinically utilized KOP-r agonist nalfurafine in combination with low-dose naltrexone has potential in alcoholism treatment.
- |||| Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Clinical: For less critical patients....IBD can sometimes be managed with either Saccharomyces Boulardii (OTC), Low Dose Naltrexone (https://t.co/hf5FWFCf8V) , and/or cannabis. But you'll rarely hear this from conventional medicine. Shame. (40+ yrs with IBD) (Twitter) - Sep 3, 2020
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - Sep 2, 2020
P2, N=36, Recruiting, Sponsor: University of Pennsylvania
The clinically utilized KOP-r agonist nalfurafine in combination with low-dose naltrexone has potential in alcoholism treatment. Trial completion date: Apr 2023 --> Dec 2021 | Trial primary completion date: Apr 2023 --> Dec 2021
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Journal: Low-dose naltrexone as a treatment for chronic fatigue syndrome. (Pubmed Central) - Aug 15, 2020
Treatment doses ranged from 4 to 12 mg. Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2/3 trial: LDN and tDCS in Fibromyalgia (clinicaltrials.gov) - Aug 6, 2020
P2/3, N=92, Completed, Sponsor: Centro Universitario La Salle
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Low-Dose Naltrexone: An Inexpensive Medicine for Many Ills? https://t.co/R4yxa2y3tt via @medscape @RepTomSuozzi (Twitter) - Jul 31, 2020
- | fluorouracil / Generic mfg., Lodonal (naltrexone low dose oral) / Immune Therap
Preclinical, Journal, IO Biomarker: The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response. (Pubmed Central) - Jul 16, 2020
Clinical trials may be warranted to explore the potential use of naltrexone in people with these debilitating illnesses which currently have no licensed treatments available. The current study suggested that LDN may play a role in inhibiting cancer cell growth and highlights the possibility of promising combination with cancer chemotherapeutics, which guarantee further clinical studies for approval.
- Lodonal (naltrexone low dose oral) / Immune Therap
[VIRTUAL] Endogenous Modulation and Central Sensitization in New Daily Persistent Headache in Children: Preliminary Findings () - Jul 15, 2020 - Abstract #AHS2020AHS_141;
The study results are limited by the amount of participants as data collection is ongoing. However, as information regarding the pathophysiology of NDPH is extremely scarce, it may be instructive important to share preliminary data with a plan to complete the work in 150 patients, supported by the generosity of the Migraine Research Foundation.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - Jul 8, 2020
P2, N=36, Recruiting, Sponsor: University of Pennsylvania
However, as information regarding the pathophysiology of NDPH is extremely scarce, it may be instructive important to share preliminary data with a plan to complete the work in 150 patients, supported by the generosity of the Migraine Research Foundation. Trial completion date: Dec 2020 --> Apr 2023 | Trial primary completion date: Dec 2020 --> Apr 2023
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: Low-dose Naltrexone for Bladder Pain Syndrome (clinicaltrials.gov) - Jun 29, 2020
P2, N=40, Not yet recruiting, Sponsor: Stanford University
- | Lodonal (naltrexone low dose oral) / Immune Therap
Journal: Low-dose Naltrexone Therapy for Psoriasis. (Pubmed Central) - Jun 28, 2020
Low-dose naltrexone regulates lymphocyte responses, reduces cytokine production, and likely reduces mast cell activity. Low-dose naltrexone is safe, inexpensive, and appears be effective in this open-label study.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Cytocom
Preclinical, Journal: Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo. (Pubmed Central) - Jun 27, 2020
In additon, LDN indirectly reduced the number of tumor-associated macrophages (TAMs), mainly M2 macrophages, and decreased expression of anti-inflammatory factor IL-10 in the serum of nude mice. These findings demonstrate that LDN could be a potential treatment for cervical cancer.
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Combination therapy: Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis (clinicaltrials.gov) - Jun 22, 2020
P3, N=160, Recruiting, Sponsor: Milton S. Hershey Medical Center
These findings demonstrate that LDN could be a potential treatment for cervical cancer. Active, not recruiting --> Recruiting
- | gabapentin / Generic mfg.
Trial initiation date: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin (clinicaltrials.gov) - Jun 18, 2020
P2, N=45, Not yet recruiting, Sponsor: Boston Medical Center
Active, not recruiting --> Recruiting Initiation date: Jun 2020 --> Sep 2020
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P2 trial: Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia (clinicaltrials.gov) - May 31, 2020
P2, N=50, Active, not recruiting, Sponsor: Washington University School of Medicine
- | Lodonal (naltrexone low dose oral) / Immune Therap
low dose naltrexone- from someone who knows. (Twitter) - May 30, 2020
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Trial primary completion date: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - May 11, 2020
P2, N=36, Recruiting, Sponsor: University of Pennsylvania
Initiation date: Jun 2020 --> Sep 2020 Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2020 --> Dec 2020
- ||| Lodonal (naltrexone low dose oral) / Immune Therap
Good news here from @GavinGiovannoni re #Covid19 for people with MS on DMTs. Wonder about other, off label, treatments that modulate the immune system, eg, low-dose naltrexone? (Twitter) - Apr 10, 2020
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed, Enrollment change, Combination therapy: Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis (clinicaltrials.gov) - Apr 10, 2020
P3, N=2, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Recruiting | Trial primary completion date: Aug 2020 --> Dec 2020 Recruiting --> Active, not recruiting | N=160 --> 2
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed, Enrollment change: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - Mar 24, 2020
P2, N=36, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting | N=160 --> 2 Recruiting --> Active, not recruiting | N=60 --> 36
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LDN-CRPS: Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome (clinicaltrials.gov) - Mar 18, 2020
P=N/A, N=40, Recruiting, Sponsor: Stanford University
Recruiting --> Active, not recruiting | N=60 --> 36 Trial completion date: Jun 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2021
- | Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
New P4 trial: IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone (clinicaltrials.gov) - Mar 18, 2020
P4, N=44, Not yet recruiting, Sponsor: NorthShore University HealthSystem
- | Lodonal (naltrexone low dose oral) / Immune Therap
Journal: Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias? (Pubmed Central) - Feb 25, 2020
For these cases, LDN would be a possible alternative to be added to the therapeutic arsenal owing to its anti-inflammatory properties, analgesic potential, low cost, and few adverse effects described. Further studies are needed to standardize dosing, better understand its mechanism of action, and evaluate its potential therapeutic indications.
- topiramate / Generic mfg., lithium / Generic mfg., Lodonal (naltrexone low dose oral) / Immune Therap
[VIRTUAL] Hailey-Hailey disease - a rare disease, even in psychiatry! (Station 02) - Feb 20, 2020 - Abstract #EPA2020EPA_3431;
Studies indicate that there is a genetic association between HHD and affective disorder, envolving mutations in the ATP2C1 gene encoding a secretory pathway calcium ATPase1. Multiple therapies are available with inconsistent outcomes and potentially severe adverse effects.
- | naltrexone / Generic mfg.
New P2 trial: Fibromyalgia and Naltrexone: The FINAL Study (clinicaltrials.gov) - Feb 17, 2020
P2, N=100, Recruiting, Sponsor: Odense University Hospital
- | Lodonal (naltrexone low dose oral) / Immune Therap
Journal: Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes. (Pubmed Central) - Feb 14, 2020
Low-dose naltrexone (LDN) may also have utility in improving mood disorders and the potential to enhance the quality of life. This article will therefore propose the potential off-label use of LDN in management of nonmalignant pain in the palliative medicine setting.
- || Lodonal (naltrexone low dose oral) / Immune Therap
Clinical, Journal: Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety. (Pubmed Central) - Feb 13, 2020
In the starting days of detoxification, VLNTX can reduce the withdrawal symptoms, but the efficacy declined by passing time. Further studies are needed to test the utility of this new therapeutic approach.
- Comprehensive pain management program and low dose naltrexone for patients with complex regional pain syndrome (CRPS) () - Feb 11, 2020 - Abstract #ISPRM2020ISPRM_680;
Difficulty in brushing hair and opening jars.Medications: Cymbalta, Gabapentin, Lyrica, and Medical Marijuana Intervention: 21-day CPMP and LDNFollow up: Pain 2/10...edema, allodynia, distorted nails, and decreased grip strength.Medications: Amitriptyline, Cymbalta, Gabapentin...These patients reduced utilization of pain medications, and achieved almost complete remission of CRPS symptoms. A multi-modal interventional approach should be considered as a treatment option for CRPS.